TOKYO, Oct 19 (Bernama-BUSINESS WIRE) -- Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the
Group’), the global pharmaceuticals and services group, has launched its
Japanese business with the opening of an office in Tokyo, Japan. The
establishment of Clinigen K.K. further expands the Group’s presence in Asia,
following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the
launch, Clinigen K.K. will transfer the Marketing Authorisation for its lead
Specialty Pharmaceutical (SP) product Foscavir® (foscarnet sodium) back from
Nobel Pharma on 1 November 2016. Nobel Pharma has been the distribution partner
for Foscavir in Japan since 2011.
Foscavir is indicated to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) or Cytomegalovirus viremia and cytomegalovirus disease in hematopoietic stem cell transplant (HSCT) patients. Japan was the first market where Clinigen successfully achieved a new license extension for HSCT patients in 2011.
No comments:
Post a Comment